Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown.

BRYHALI® (halobetasol propionate) lotion, 0.01% is indicated for the topical treatment of plaque psoriasis in adults.

Apply a thin layer of BRYHALI Lotion to the affected areas once daily. Treatment beyond 8 weeks is not recommended. Discontinue treatment if control is achieved before 8 weeks. Do not use with occlusive dressings unless directed by a physician. Avoid use on the face, groin, or axillae.

The most common adverse reactions (≥1%) were upper respiratory tract infection, application site dermatitis and hyperglycemia.

None

Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression was observed and may occur with the potential for glucocorticosteroid insufficiency during or after treatment. Systemic effects of topical corticosteroids may also include Cushing’s syndrome, hyperglycemia, and glucosuria. Systemic absorption may require evaluation for HPA axis suppression. Use of potent corticosteroids on large areas, for prolonged durations, under occlusive dressings, or on an altered skin barrier may increase systemic exposure. Children may be more susceptible to systemic toxicity when treated with topical corticosteroids. Local adverse reactions may include atrophy, striae, telangiectasias, hypopigmentation, and allergic contact dermatitis. Some local adverse reactions may be irreversible. Use of topical corticosteroids may increase the risk of posterior subcapsular cataracts and glaucoma. (See Full Prescribing Information.)